Metrics as of 10/13/2026, 06:55 PM (Berlin time), refresh in progress.
Stereotaxis Stock
Stereotaxis, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- David L. Fischel
- Employees
- 131
- Market cap
- $104 M
- IPO
- 12/08/2004
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers…
Stereotaxis stock: price history
1D
-7.0%
1W
-7.8%
1M
-17.8%
6M
-47.8%
YTD
-53.9%
1Y
-65.5%
2Y
-46.5%
5Y
-79.6%
10Y
+23.3%
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~13% stronger price swings than usual
Ask the agents about Stereotaxis
Analyst assessment of Stereotaxis
PRICE TARGET LOW
US$3.50
CONSENSUS
US$3.50
MEDIAN
US$3.50
PRICE TARGET HIGH
US$3.50
0
STRONG BUY
12
BUY
0
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 27/08/2026
Stereotaxis stock metrics
P/E
-4.29
P/B
6.07
EV/EBITDA
-4.75
RETURN ON EQUITY
-25.6%
NET MARGIN
-58.3%
DEBT/EQUITY
0.3
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.0%
FLOAT SHARES
69,576,802
AVG. DAILY VOLUME (30D)
535,489
Insider transactions (SEC)
Menawat Arun Swarup
Curet Myriam
Fischel Nathan
Levin Ross B
Benfer David
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Stereotaxis stock
What does Stereotaxis do?
Stereotaxis, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is David L. Fischel, the company employs around 131 people.
The IPO was on 12/08/2004; the stock trades on AMEX under the ticker STXS.
What do analysts say about Stereotaxis stock?
12 analysts rate the stock, the consensus is Buy (as of 27/08/2026).
The average price target is US$3.50, ranging from US$3.50 to US$3.50, with a median of US$3.50.
This is an external assessment, not a statement by Market Jury.
When does Stereotaxis report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 13% stronger than usual.
Does Stereotaxis pay a dividend?
No, Stereotaxis currently does not pay a dividend.
Which stocks are comparable to Stereotaxis?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Stereotaxis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Stereotaxis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.